Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Moskowitz

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Cell Death & Disease|May 24, 2014
The CT20 peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruptionM W Lee, R Bassiouni, N A Sparrow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamideC S Portlock, J Qin, P Schaindlin, et al.
The International Journal of Neuroscience|June 14, 2011
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behavioursJoseph H Friedman, P Agarwal, R Alcalay, et al.
Neurology|January 26, 2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dGS M Hersch, S Gevorkian, K Marder, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Cell Death & Disease|May 24, 2014
The CT20 peptide causes detachment and death of metastatic breast cancer cells by promoting mitochondrial aggregation and cytoskeletal disruptionM W Lee, R Bassiouni, N A Sparrow, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamideC S Portlock, J Qin, P Schaindlin, et al.
The International Journal of Neuroscience|June 14, 2011
Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behavioursJoseph H Friedman, P Agarwal, R Alcalay, et al.
Neurology|January 26, 2006
Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dGS M Hersch, S Gevorkian, K Marder, et al.
Pageof 4